Emerging reverse transcriptase inhibitors for HIV-1 infection

MA Rai, S Pannek, CJ Fichtenbaum - Expert opinion on emerging …, 2018 - Taylor & Francis
ABSTRACT Introduction: There are 36.7 million people living with HIV with 20.9 million
having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase …

[HTML][HTML] Emerging Reverse Transcriptase Inhibitors for HIV-1 Infection

MA Rai, S Pannek, CJ Fichtenbaum - Expert opinion on emerging …, 2018 - ncbi.nlm.nih.gov
Abstract Introduction: There are 36.7 million people living with HIV with 20.9 million having
access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors …

Emerging reverse transcriptase inhibitors for HIV-1 infection.

MA Rai, S Pannek, CJ Fichtenbaum - Expert Opinion on Emerging …, 2018 - europepmc.org
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral
therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain …

Emerging reverse transcriptase inhibitors for HIV-1 infection

MA Rai, S Pannek… - Expert opinion on …, 2018 - pubmed.ncbi.nlm.nih.gov
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral
therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain …

Emerging reverse transcriptase inhibitors for HIV-1 infection.

MA Rai, S Pannek, CJ Fichtenbaum - Expert Opinion on Emerging …, 2018 - europepmc.org
Abstract Introduction: There are 36.7 million people living with HIV with 20.9 million having
access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors …